Per Soelberg Sørensen

Per Soelberg Sørensen

Auto-generated profile, based on publicly available information

Per Soelberg Sørensen

Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital Rigshospitalet

Research Focus & Metrics

Academic Career Length

56Years (1971-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in The Lancet Neurology
Verified
Journal Article
Closed access
ATAlan J Thompson
Alan J Thompson
BBBrenda L Banwell
Brenda L Banwell
FBFrederik Barkhof
Frederik Barkhof
WCWilliam M Carroll
William M Carroll
TCTimothy Coetzee
Timothy Coetzee
JCJeffrey A Cohen
Jeffrey A Cohen

15 July 2014 in Neurology
Verified
Journal Article
Open access
PDF file
FLFred D. Lublin
Fred D. Lublin
SRStephen C. Reingold
Stephen C. Reingold
JCJeffrey A. Cohen
Jeffrey A. Cohen
GCGary R. Cutter
Gary R. Cutter
PSPer Soelberg Sørensen
Per Soelberg Sørensen
CPChris H. Polman
Chris H. Polman
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

29 September 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ABAshley H Beecham
Ashley H Beecham
NPNikolaos A Patsopoulos
Nikolaos A Patsopoulos
DXDionysia K Xifara
Dionysia K Xifara
MDMary F Davis
Mary F Davis
AKAnu Kemppinen
Anu Kemppinen
JMJacob McCauley
Jacob McCauley
The International Multiple Sclerosis Genetics Consortium reports the discovery of 48 new susceptibility variants for multiple sclerosis through targeted follow-up of immune-related loci. They also report fine mapping of association signals at established susceptibility loci and provide insights into the immune system processes underlying this disease. Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 potentially associated regions (P < 1.0 × 10−4). In a replication phase, we combined these data with previous genome-wide association study (GWAS) data from an independent 14,802 subjects with multiple sclerosis and 26,703 healthy controls. In these 80,094 individuals of European ancestry, we identified 48 new susceptibility variants (P < 5.0 × 10−8), 3 of which we found after conditioning on previously identified variants. Thus, there are now 110 established multiple sclerosis risk variants at 103 discrete loci outside of the major histocompatibility complex. With high-resolution Bayesian fine mapping, we identified five regions where one variant accounted for more than 50% of the posterior probability of association. This study enhances the catalog of multiple sclerosis risk variants and illustrates the value of fine mapping in the resolution of GWAS signals.

31 March 2009 in Brain
Verified
Journal Article
Open access
PDF file
JFJosa M Frischer
Josa M Frischer
SBStephan Bramow
Stephan Bramow
ADAssunta Dal-Bianco
Assunta Dal-Bianco
CLClaudia F. Lucchinetti
Claudia F. Lucchinetti
HRHelmut Rauschka
Helmut Rauschka
HLHans Lassmann
Hans Lassmann
Some recent studies suggest that in progressive multiple sclerosis, neurodegeneration may occur independently from inflammation. The aim of our study was to analyse the interdependence of inflammation, neurodegeneration and disease progression in various multiple sclerosis stages in relation to lesional activity and clinical course, with a particular focus on progressive multiple sclerosis. The study is based on detailed quantification of different inflammatory cells in relation to axonal injury in 67 multiple sclerosis autopsies from different disease stages and 28 controls without neurological disease or brain lesions. We found that pronounced inflammation in the brain is not only present in acute and relapsing multiple sclerosis but also in the secondary and primary progressive disease. T- and B-cell infiltrates correlated with the activity of demyelinating lesions, while plasma cell infiltrates were most pronounced in patients with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS) and even persisted, when T- and B-cell infiltrates declined to levels seen in age matched controls. A highly significant association between inflammation and axonal injury was seen in the global multiple sclerosis population as well as in progressive multiple sclerosis alone. In older patients (median 76 years) with long-disease duration (median 372 months), inflammatory infiltrates declined to levels similar to those found in age-matched controls and the extent of axonal injury, too, was comparable with that in age-matched controls. Ongoing neurodegeneration in these patients, which exceeded the extent found in normal controls, could be attributed to confounding pathologies such as Alzheimer's or vascular disease. Our study suggests a close association between inflammation and neurodegeneration in all lesions and disease stages of multiple sclerosis. It further indicates that the disease processes of multiple sclerosis may die out in aged patients with long-standing disease.

1 May 2010 in The Lancet Neurology
Verified
Journal Article
Closed access
NKNils Koch-Henriksen
Nils Koch-Henriksen
PSPer Soelberg Sørensen
Per Soelberg Sørensen

4 February 2010 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
GGGavin Giovannoni
Gavin Giovannoni
GCGiancarlo Comi
Giancarlo Comi
SCStuart Cook
Stuart Cook
KRKottil Rammohan
Kottil Rammohan
PRPeter Rieckmann
Peter Rieckmann
SGSteven J. Greenberg
Steven J. Greenberg
Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing–remitting multiple sclerosis. We randomly assigned 1326 patients in an approximate 1:1:1 ratio to receive one of two cumulative doses of cladribine tablets (either 3.5 mg or 5.25 mg per kilogram of body weight) or matching placebo, given in two or four short courses for the first 48 weeks, then in two short courses starting at week 48 and week 52 (for a total of 8 to 20 days per year). The primary end point was the rate of relapse at 96 weeks. Among patients who received cladribine tablets (either 3.5 mg or 5.25 mg per kilogram), there was a significantly lower annualized rate of relapse than in the placebo group (0.14 and 0.15, respectively, vs. 0.33; P<0.001 for both comparisons), a higher relapse-free rate (79.7% and 78.9%, respectively, vs. 60.9%; P<0.001 for both comparisons), a lower risk of 3-month sustained progression of disability (hazard ratio for the 3.5-mg group, 0.67; 95% confidence interval [CI], 0.48 to 0.93; P=0.02; and hazard ratio for the 5.25-mg group, 0.69; 95% CI, 0.49 to 0.96; P=0.03), and significant reductions in the brain lesion count on magnetic resonance imaging (MRI) (P<0.001 for all comparisons). Adverse events that were more frequent in the cladribine groups included lymphocytopenia (21.6% in the 3.5-mg group and 31.5% in the 5.25-mg group, vs. 1.8%) and herpes zoster (8 patients and 12 patients, respectively, vs. no patients). Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks. The benefits need to be weighed against the risks. (ClinicalTrials.gov number, NCT00213135.)